Status:
COMPLETED
Multisystem Cell Therapy for Improvement of Urinary Continence
Lead Sponsor:
University of Zurich
Collaborating Sponsors:
University Hospital Tuebingen
Salzburger Landeskliniken
Conditions:
Urinary Stress Incontinence
Eligibility:
FEMALE
20-60 years
Phase:
PHASE1
Brief Summary
The rising success of cell therapies places an increasing burden on health care costs. Consequently, the need to reduce production costs while maintaining quality has been widely acknowledged. In addi...
Detailed Description
muscle precursor cells (MPCs) will be isolated from biopsies of the lower leg of patients, seeded, expanded and cultivated in vitro in a GMP facility to generate vital muscle cells dedicated for impla...
Eligibility Criteria
Inclusion
- Adult women 20y-60y
- Incontinence \>/= grade I since at least 6 months
- Predominant clinical diagnosis of SUI
- Candidate for a surgical treatment (artificial urinary sphincter, synthetic compressive tapes or adjustable balloons).
- Post void residual volume of \<100 ml (exclusion of overflow incontinence)
- Can independently use toilet without difficulty
- Capacity to answer the questionnaires of evaluation
- Negative blood test for: Human immunodeficiency virus (HIV 1/2), Hepatitis B HBsAg, Anti HBc, Hepatitis C Anti-HCV-Ab, Syphilis
- Competent to comprehend, sign and date informed consent form before any study-specific procedure is performed
Exclusion
- History of anti-incontinence or prolapse surgery.
- Previous diagnosis of any of the following conditions, disorders, or diseases of the urinary tract:
- Clinically significant cystocele or rectocele
- Ureteric bladder, urethral or rectal fistula
- Uncorrected congenital abnormality leading to urinary incontinence
- Interstitial cystitis
- Urinary urgency that results in leakage (as a predominant symptom)
- Adult enuresis
- Urodynamically proven detrusor instability
- Sensory urgency defined as first sensation of bladder fill (urge to void) of \<100 ml; bladder capacity of \<300 ml
- No sensation at any time during the simple filling cystometry procedure
- Known urethral stenosis (ureterocystoscopy) or urethral diverticulum
- History of urogenital cancer or history of pelvic radiotherapy
- Women who are pregnant, breast feeding or \<12 months postpartum Note: Female subjects who are surgically sterilized, hysterectomized or post-menopausal for longer than 2 years are not considered as having child bearing potential. No pregnancy test will be performed for this population.
- Untreated symptomatic urinary tract infection
- Fever (as defined by ≥ 38,5°C, axillar measurement), any infectious disease, cold or flu within the last 7 days
- Unstable severe systemic disease including uncontrolled hypertension, unstable angina, or myocardial infarction, severe coagulation disorders, bleeding diathesis, emboli, thrombophlebitis, infectious diseases, poor wound healing, and poorly controlled diabetes mellitus within 6 months before enrolment
- Any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results.
- Known allergy or intolerance of at least one of the active ingredients or excipients of the investigational products
- Known allergy or intolerance of Penicillin or Streptomycin
- Known genetically determined or acquired muscular disease.
- Known Neurological disorder (Parkinson's disease, multiple sclerosis, spina bifida, medullary traumatism).
- Medication regimen including estrogens, anti-estrogens or diuretics where dose and/or frequency has not been stable for at least the past 12 weeks or is anticipated to change during the course of the study.
- Chronic use of any of the following drugs and not stopped for at least 2 weeks prior to inclusion into the study: selective serotonin and norepinephrine reuptake inhibitor antidepressant (SSNRI), alpha-receptor antagonists/agonists, beta-3-receptor agonists or anticholinergic/-muscarinic drugs.
- Chronic use of any of the following drugs and not stopped for at least 6 months prior to inclusion into the study: Antidepressants or neuroleptic drugs.
Key Trial Info
Start Date :
January 22 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 21 2021
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT03439527
Start Date
January 22 2020
End Date
October 21 2021
Last Update
November 3 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zurich
Zurich, Switzerland, 8091